Document:

pure_Ex_10_31

		
			Exhibit 10.31
		

		
			 
		

		
			REGISTRATION RIGHTS AGREEMENT
		

		
			 
		

		
			This REGISTRATION RIGHTS AGREEMENT (the “Agreement”) is made effective as of October 8,  2015, by and among Pure Bioscience,  Inc., a  Delaware corporation (the “Company”), and each of the persons executing a copy of this Agreement (each an “Investor” and, collectively, the “Investors”).
		

		
			 
		

		
			The parties hereby agree as follows:
		

		
			 
		

		
			1.Certain Definitions.
		

		
			 
		

		
			As used in this Agreement, the following terms shall have the following meanings:
		

		
			 
		

		
			“Affiliate” shall mean, with respect to any person, any other person which directly or indirectly controls, is controlled by, or is under common control with, such person.
		

		
			 
		

		
			“Business Day” shall mean a day, other than a Saturday or Sunday, on which banks in New York City are open for the general transaction of business.
		

		
			 
		

		
			“Common Stock” shall mean the Company’s common stock, par value $0.01 per share, and any securities into which such shares may hereinafter be reclassified.
		

		
			 
		

		
			“Investor” or “Investors” shall mean a person or the persons executing a copy of this Agreement and the Purchase Agreement and any Affiliate of any Investor who is a subsequent holder of any Registrable Securities.
		

		
			 
		

		
			“Issuable Shares” shall mean the Purchase Shares and the Warrant Shares.
		

		
			 
		

		
			“Prospectus” shall mean (i) the prospectus included in the Registration Statement, as amended or supplemented by any prospectus supplement, with respect to the terms of the offering of any portion of the Registrable Securities covered by such Registration Statement and by all other amendments and supplements to the prospectus, including post-effective amendments and all material incorporated by reference in such prospectus, and (ii) any “free writing prospectus” as defined in Rule 405 under the 1933 Act.
		

		
			 
		

		
			“Purchase Agreement” shall mean that certain Securities Purchase Agreement by and among the Company and the purchasers named therein.  
		

		
			 
		

		
			“Purchase Shares” shall mean the shares of Common Stock acquired by an Investor pursuant to the Securities Purchase Agreement and issued at a closing thereof.
		

		
			 
		

		
			“Register,” “registered” and “registration” refer to a registration made by preparing and filing the Registration Statement or similar document in compliance with the 1933 Act (as defined below), and the declaration or ordering of effectiveness of such Registration Statement or document.
		

		
			 
		

		
			 “Registrable Securities” shall mean (i) the Purchase Shares, (ii) the Warrant Shares and (iii) any other securities issued or issuable with respect to or in exchange for the Purchase Shares or Warrant Shares; provided, that, a security shall cease to be a Registrable Security upon the earlier of (a) the date the Registration Statement becomes effective under the 1933 Act and such securities having been sold, transferred, disposed of or exchanged pursuant to such Registration Statement, (b) the date on which such securities either have been transferred pursuant to Rule 144 (or any similar provision then in effect) or are freely saleable, without condition pursuant to Rule 144, including any current public information requirements, assuming for any Warrants that contain a cashless exercise feature, that the Warrant Shares issuable pursuant to such Warrants will be issued pursuant to the terms of the cashless exercise feature or (c) the date on which such securities  are sold to the Company or cease to be outstanding.
		

		
			 
		

		
			“Registration Statement” shall mean a registration statement of the Company filed under the 1933 Act that covers the resale of any of the Registrable Securities pursuant to the provisions of this Agreement, as well as amendments and supplements to such Registration Statement, including post-effective amendments, and all exhibits
		

		
			
		

		
			

		 

		

			1

		

 

 
		

		
			and all material incorporated by reference in such Registration Statement.
		

		
			 
		

		
			“Rule 415” means Rule 415 promulgated by the SEC pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time, or any similar rule or regulation hereafter adopted by the SEC having substantially the same purpose and effect as such Rule.
		

		
			 
		

		
			“SEC” shall mean the U.S. Securities and Exchange Commission.
		

		
			 
		

		
			“Warrants” shall mean, the Warrants to purchase shares of Common Stock issued to the Investors pursuant to the Purchase Agreement.
		

		
			 
		

		
			“Warrant Shares” shall mean the shares of Common Stock issuable upon the exercise of the Warrants. 
		

		
			 
		

		
			“1933 Act” shall mean the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.
		

		
			 
		

		
			“1934 Act” shall mean the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.
		

		
			 
		

		
			2.Registration.
		

		
			 
		

		
			(a)Demand Registration.    Subject to the conditions of this Section 2, following demand by the Investors holding at least seventy-five percent (75%) of the Issuable Shares (assuming the exercise of the Warrants) that the Company file a Registration Statement covering the registration of the Registrable Securities (the “Initial Demand Request”), the Company shall, within ten (10) days of the receipt thereof, give written notice of such request to all Investors (the “Registration Notice”).  Upon written notice received by the Company within ten (10) days of the mailing of the Registration Notice from Investors requesting that their respective Registrable Securities be registered pursuant to the Registration Statement (the “Additional Demand Requests”), the Company shall use its commercially reasonable efforts to file, as soon as practicable and in any event within 60 days of receipt of the Additional Demand Requests, a Registration Statement covering the resale of Registrable Securities that the Investors request to be registered pursuant to this Section 2 (a “Demand Registration”).  Notwithstanding the foregoing, the Company will in no event be required to effect more than one Demand Registration in total.  The Company’s obligation pursuant to this Section 2 is conditioned upon the Investors providing the information contemplated in Section 5.  Subject to any SEC comments, such Registration Statement shall include the plan of distribution attached hereto as Exhibit A  (the “Plan of Distribution”).  Such Registration Statement also shall cover, to the extent allowable under the 1933 Act (including Rule 416), such indeterminate number of additional shares of Common Stock resulting from stock splits, stock dividends or similar transactions with respect to the Registrable Securities.  Except as expressly provided in the Purchase Agreement, such Registration Statement shall not include any shares of Common Stock or other securities for the account of any other holder without the prior written consent of the Investors holding a majority of the Registrable Securities.  The Registration Statement (and each amendment or supplement thereto, and any request for acceleration of effectiveness thereof) shall be provided in accordance with Section 2(c) to the Investors and their counsel prior to its filing or other submission.  
		

		
			 
		

		
			(b)Expenses.  The Company will pay all expenses associated with the registration, including filing and printing fees, the Company’s counsel and accounting fees and expenses, costs associated with clearing the Registrable Securities for sale under applicable state securities laws, listing fees, reasonable fees and expenses of one counsel to the Investors and the Investors’ reasonable expenses in connection with the registration, but excluding discounts, commissions, fees of underwriters, selling brokers, dealer managers or similar securities industry professionals with respect to the Registrable Securities being sold.
		

		
			 
		

		
			(c)Effectiveness.  The Company shall use its commercially reasonable efforts to cause such Registration Statement to be declared effective under the 1933 Act as promptly as reasonably practicable after the filing thereof.  Any request for acceleration of the Registration Statement shall seek effectiveness at 4:01 p.m., New York time, or as soon thereafter as practicable.  The Company shall notify the Investors by facsimile or e-mail as promptly as practicable, and in any event, prior to 9:00 a.m., New York time, on the day after the Registration Statement is declared effective, shall file with the SEC under Rule 424 a final Prospectus as promptly as practicable, and in any
		

		
			
		

		
			

		 

		

			2

		

 

 
		

		
			event, prior to 9:00 a.m., New York time, on the day after the Registration Statement is declared effective, and shall advise the Investors in writing that either (i) it has complied with the requirements of Rule 172 or (ii) it is unable to satisfy the conditions of Rule 172 and, as a result, Investors are required to deliver a copy of the Prospectus in connection with any sales of Registrable Securities (in which case, the Company shall deliver to the Investors a copy of the Prospectus to be used in connection with the sale or other disposition of the securities covered thereby).  Notwithstanding the foregoing, there shall be no monetary penalty or liquidated damages imposed upon the Company if the Registration Statement is not declared effective by the SEC.
		

		
			 
		

		
			(d)Deferral and Suspension. At any time after receiving a Demand Request or after the Registration Statement has become effective, the Company may defer the filing of or suspend the use of any such Registration Statement upon giving written notice of such action to the Investors with a certificate signed by the Chief Executive Officer of the Company stating that in the good faith judgment of the Board of Directors, the filing or use of the Registration Statement covering the Registrable Securities would be seriously detrimental to the Company or its stockholders at such time and that the Board of Directors concludes, as a result, that it is in the best interests of the Company or its stockholders to defer the filing or suspend the filing or suspend the use of such Registration Statement at such time. The Company shall have the right to defer the filing of or suspend the use of such Registration Statement for a period of up to an aggregate of one hundred twenty (120) days from the date the Company notifies the Investors of such deferral or suspension in any twelve (12) month period; provided, that the Company may not invoke this right more than once in any twelve (12) month period. In the case of the suspension of use of any effective Registration Statement, the Investors, immediately upon receipt of notice thereof from the Company, shall discontinue any sales of Registrable Securities pursuant to such Registration Statement until advised in writing by the Company that the use of such Registration Statement may be resumed. In the case of a deferred Registration Statement, the Company shall provide prompt written notice to the Investors of (i) the Company’s decision to file or seek effectiveness of the Registration Statement following such deferral and (ii) the effectiveness of such Registration Statement.
		

		
			 
		

		
			3.Company Obligations.  The Company will use its commercially reasonable efforts to effect the registration of the Registrable Securities in accordance with the terms hereof, and pursuant thereto the Company will, as expeditiously as possible:
		

		
			 
		

		
			(a)use its commercially reasonable efforts to cause such Registration Statement to become effective as provided herein and to remain continuously effective for a period that will terminate when the Purchase Shares, (ii) the Warrant Shares and (iii) any other securities issued or issuable with respect to or in exchange for Registrable Securities, as applicable, cease to be Registrable Securities; 
		

		
			 
		

		
			(b)prepare and file with the SEC such amendments and post-effective amendments to the Registration Statement and the Prospectus as may be necessary to keep the Registration Statement effective for the Effectiveness Period and to comply with the provisions of the 1933 Act and the 1934 Act with respect to the distribution of all of the Registrable Securities covered thereby;
		

		
			 
		

		
			(c)furnish to each of the Investors and their single designated legal counsel (i) promptly after the same is prepared and publicly distributed, filed with the SEC, or received by the Company (but not later than two (2) Business Days after the filing date, receipt date or sending date, as the case may be) one (1) copy of the Registration Statement and any amendment thereto, the preliminary prospectus and Prospectus and any amendment or supplement thereto, and (ii) such number of copies of a Prospectus, including a preliminary prospectus, and all amendments and supplements thereto and such other documents as each Investor may reasonably request in order to facilitate the disposition of the Registrable Securities owned by such Investor that are covered by the Registration Statement;
		

		
			 
		

		
			(d)use commercially reasonable efforts to (i) prevent the issuance of any stop order or other suspension of effectiveness and, (ii) if such order is issued, obtain the withdrawal of any such order at the earliest possible moment;
		

		
			 
		

		
			(e)to the extent required by applicable law, prior to any public offering of Registrable Securities, use commercially reasonable efforts to (i) register or qualify or cooperate with the Investors and their counsel in connection with the registration or qualification of such Registrable Securities for offer and sale under the securities or blue sky laws of such jurisdictions reasonably requested by the Investors and (ii) do any and all other acts or
		

		
			
		

		
			

		 

		

			3

		

 

 
		

		
			things commercially reasonable or advisable to enable the distribution in such jurisdictions of the Registrable Securities covered by the Registration Statement; provided, however, that the Company shall not be required in connection therewith or as a condition thereto to (i) qualify to do business in any jurisdiction where it would not otherwise be required to qualify but for this Section 3(e), (ii) subject itself to general taxation in any jurisdiction where it would not otherwise be so subject but for this Section 3(e), or (iii) file a general consent to service of process in any such jurisdiction;
		

		
			 
		

		
			(f)use commercially reasonable efforts to cause all Registrable Securities covered by the Registration Statement to be listed on each securities exchange, interdealer quotation system or other market on which similar securities issued by the Company are then listed; and
		

		
			 
		

		
			(g)otherwise use commercially reasonable efforts to comply with all applicable rules and regulations of the SEC under the 1933 Act and the 1934 Act, including, without limitation, Rule 172 under the 1933 Act, file any final Prospectus, including any supplement or amendment thereof, with the SEC pursuant to Rule 424 under the 1933 Act, promptly inform the Investors in writing if, at any time during the Effectiveness Period, the Company does not satisfy the conditions specified in Rule 172 and, as a result thereof, the Investors are required to deliver a Prospectus in connection with any disposition of Registrable Securities, and take such other actions as may be reasonably necessary to facilitate the registration of the Registrable Securities hereunder.
		

		
			 
		

		
			(h)With a view to making available to the Investors the benefits of Rule 144 of the 1933 Act (or its successor rule) and any other rule or regulation of the SEC that may at any time permit the Investors to sell shares of Common Stock to the public without registration, the Company covenants and agrees to:  (i) use its commercially reasonable efforts to make and keep public information available, as those terms are understood and defined in Rule 144, until the earlier of (A) six months after such date as all of the Registrable Securities may be resold pursuant to Rule 144 without regard to any volume limitation requirements under Rule 144 or (B) such date as all of the Registrable Securities shall have been resold and (ii) use its commercially reasonable efforts to file with the SEC in a timely manner all reports and other documents required of the Company under the 1934 Act.
		

		
			 
		

		
			4.Due Diligence Review; Information.  
		

		
			 
		

		
			(a)The Company shall make available, during normal business hours, for inspection and review by the Investors, advisors to and representatives of the Investors (who may or may not be affiliated with the Investors and who are reasonably acceptable to the Company), all financial and other records, all SEC Filings (as defined in the Purchase Agreement) and other filings with the SEC, and all other corporate documents and properties of the Company as may be reasonably necessary for the purpose of such review, and cause the Company’s officers, directors and employees, within a reasonable time period, to supply all such information reasonably requested by the Investors or any such representative, advisor or underwriter in connection with such Registration Statement (including, without limitation, in response to all questions and other inquiries reasonably made or submitted by any of them), prior to and from time to time after the filing and effectiveness of the Registration Statement for the sole purpose of enabling the Investors and such representatives, advisors and underwriters and their respective accountants and attorneys to conduct initial and ongoing due diligence with respect to the Company and the accuracy of such Registration Statement.
		

		
			 
		

		
			(b)The Company shall not disclose material nonpublic information to the Investors, or to advisors to or representatives of the Investors, unless prior to disclosure of such information the Company identifies such information as being material nonpublic information and provides the Investors, such advisors and representatives with the opportunity to accept or refuse to accept such material nonpublic information for review and any Investor wishing to obtain such information enters into an appropriate confidentiality agreement with the Company with respect thereto.
		

		
			 
		

		
			5.Obligations of the Investors.
		

		
			 
		

		
			(a)Each Investor shall, upon request of the Company, use its commercially reasonable efforts to furnish in writing to the Company such information regarding itself, the Registrable Securities held by it and the intended method of disposition of the Registrable Securities held by it, as shall be reasonably required by the provisions of this Agreement to effect the registration of such Registrable Securities and shall execute such documents in
		

		
			
		

		
			

		 

		

			4

		

 

 
		

		
			connection with such registration as the Company may reasonably request, including a completed questionnaire in the form attached hereto as Exhibit B.  At least twenty (20) Business Days prior to the first anticipated filing date of the Registration Statement, the Company shall notify each Investor of the information the Company requires from such Investor if such Investor has made a Demand Notice or Additional Demand Notice.  An Investor shall provide such information to the Company at least ten (10) Business Days prior to the first anticipated filing date of such Registration Statement if such Investor if such Investor has made a Demand Request or an Additional Demand Request.
		

		
			 
		

		
			(b)Each Investor, by its acceptance of the Registrable Securities agrees to cooperate with the Company as reasonably requested by the Company in connection with the preparation and filing of the Registration Statement hereunder.
		

		
			 
		

		
			6.Indemnification.
		

		
			 
		

		
			(a)Indemnification by the Company.  The Company will indemnify and hold harmless each Investor and its officers, directors, members, employees and agents, successors and assigns, and each other person, if any, who controls such Investor within the meaning of the 1933 Act, against any losses, claims, damages or liabilities, joint or several, to which they may become subject under the 1933 Act or otherwise, insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon: (i) any untrue statement or alleged untrue statement of any material fact contained in the Registration Statement, any preliminary Prospectus or final Prospectus, or any amendment or supplement thereof; (ii) any blue sky application or other document executed by the Company specifically for that purpose or based upon written information furnished by the Company filed in any state or other jurisdiction in order to qualify any or all of the Registrable Securities under the securities laws thereof (any such application, document or information herein called a “Blue Sky Application ”); (iii) the omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading; or (iv) any violation by the Company or its agents of any rule or regulation promulgated under the 1933 Act applicable to the Company or its agents and relating to action or inaction required of the Company in connection with such registration;  provided  , however, that the Company will not be liable in any such case if and to the extent that any such loss, claim, damage or liability arises out of or is based upon an untrue statement or alleged untrue statement or omission or alleged omission so made in conformity with information furnished by an Investor or any controlling person of an Investor in writing specifically for use in such Registration Statement or Prospectus.
		

		
			 
		

		
			(b)Indemnification by the Investors.  Each Investor agrees, severally but not jointly, to indemnify and hold harmless, to the fullest extent permitted by law, the Company, its directors, officers, employees, stockholders and each person who controls the Company (within the meaning of the 1933 Act) against any losses, claims, damages, liabilities and expense (including reasonable attorney fees) resulting from any untrue statement of a material fact or any omission of a material fact required to be stated in the Registration Statement or Prospectus or preliminary Prospectus or amendment or supplement thereto or necessary to make the statements therein not misleading, to the extent, but only to the extent that such untrue statement or omission is contained in any information furnished in writing by such Investor or any controlling person of such Investor to the Company specifically for inclusion in such Registration Statement or Prospectus or amendment or supplement thereto.  In no event shall the liability of an Investor be greater in amount than the dollar amount of the proceeds (net of all expense paid by such Investor in connection with any claim relating to this Section 6 and the amount of any damages such Investor has otherwise been required to pay by reason of such untrue statement or omission) received by such Investor upon the sale of the Registrable Securities included in the Registration Statement giving rise to such indemnification obligation.  In addition, an Investor shall not be liable hereunder to the extent that any such loss, claim, damage, liability (or action or proceeding in respect thereof) or expense arises out of the Company’s, or any underwriter’s, or their representatives’ failure to send or give a copy of a final Prospectus, as the same may be then supplemented or amended, to the person or entity asserting an untrue statement or alleged untrue statement or omission or alleged omission at or prior to the written confirmation of the sale of securities to such person or entity if such statement or omission was corrected in such final Prospectus.
		

		
			 
		

		
			(c)Conduct of Indemnification Proceedings.  Any person entitled to indemnification hereunder shall (i) give prompt notice to the indemnifying party of any claim with respect to which it seeks indemnification and (ii) permit such indemnifying party to assume the defense of such claim with counsel reasonably satisfactory to the indemnified
		

		
			
		

		
			

		 

		

			5

		

 

 
		

		
			party; provided that any person entitled to indemnification hereunder shall have the right to employ separate counsel and to participate in the defense of such claim, but the fees and expenses of such counsel shall be at the expense of such person unless (a) the indemnifying party has agreed to pay such fees or expenses, (b) the indemnifying party shall have failed to assume the defense of such claim and employ counsel reasonably satisfactory to such person or (c) in the reasonable judgment of any such person, based upon written advice of its counsel, a conflict of interest exists between such person and the indemnifying party with respect to such claims (in which case, if the person notifies the indemnifying party in writing that such person elects to employ separate counsel at the expense of the indemnifying party, the indemnifying party shall not have the right to assume the defense of such claim on behalf of such person); and provided, further, that the failure of any indemnified party to give notice as provided herein shall not relieve the indemnifying party of its obligations hereunder, except to the extent that such failure to give notice shall materially adversely affect the indemnifying party in the defense of any such claim or litigation.  It is understood that the indemnifying party shall not, in connection with any proceeding in the same jurisdiction, be liable for fees or expenses of more than one separate firm of attorneys at any time for all such indemnified parties.  No indemnifying party will, except with the consent of the indemnified party, consent to entry of any judgment or enter into any settlement that does not include as an unconditional term thereof the giving by the claimant or plaintiff to such indemnified party of a release from all liability in respect of such claim or litigation.
		

		
			 
		

		
			(d)Contribution.  If for any reason the indemnification provided for in the preceding paragraphs (a) and (b) is unavailable to an indemnified party or insufficient to hold it harmless, other than as expressly specified therein, then the indemnifying party shall contribute to the amount paid or payable by the indemnified party as a result of such loss, claim, damage or liability in such proportion as is appropriate to reflect the relative fault of the indemnified party and the indemnifying party, as well as any other relevant equitable considerations.  No person guilty of fraudulent misrepresentation within the meaning of Section 11(f) of the 1933 Act shall be entitled to contribution from any person not guilty of such fraudulent misrepresentation.  In no event shall the contribution obligation of a holder of Registrable Securities be greater in amount than the dollar amount of the proceeds (net of all expenses paid by such holder in connection with any claim relating to this Section 6 and the amount of any damages such holder has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission) received by it upon the sale of the Registrable Securities giving rise to such contribution obligation.
		

		
			 
		

		
			7.Miscellaneous.
		

		
			 
		

		
			(a)Amendments and Waivers.  This Agreement may be amended or waived only by a writing signed by (i) the Company and (ii) the Investors holding at least seventy-five percent (75%) of the Issuable Shares (assuming the exercise of the Warrants).  The Company may take any action herein prohibited, or omit to perform any act herein required to be performed by it, only if the Company shall have obtained the written consent to such amendment, action or omission to act, of the Investors holding a majority of the Issuable Shares (assuming the exercise of the Warrants).
		

		
			 
		

		
			(b)Notices.  All notices and other communications provided for or permitted hereunder shall be made as set forth in the Purchase Agreement.
		

		
			 
		

		
			(c)Assignments and Transfers by Investors.  The provisions of this Agreement shall be binding upon and inure to the benefit of the Investors and their respective successors and assigns.  An Investor may transfer or assign, in whole or from time to time in part, to one or more persons its rights hereunder in connection with the transfer of Registrable Securities by such Investor to such person, provided that such transferee or assignee shall execute a copy of this Agreement and that such Investor complies with all laws applicable thereto and provides written notice of assignment to the Company promptly after such assignment is effected.
		

		
			 
		

		
			(d)Assignments and Transfers by the Company.  This Agreement may not be assigned by the Company (whether by operation of law or otherwise) without the prior written consent of the Investors holding a majority of the Issuable Shares (assuming conversion of the Notes and exercise of the Warrants), provided, however, that the Company may assign its rights and delegate its duties hereunder to any surviving or successor corporation in connection with a merger or consolidation of the Company with another corporation, or a sale, transfer or other disposition of all or substantially all of the Company’s assets to another corporation, without the prior written consent of the Investors holding a majority of the Issuable Shares (assuming conversion of the Notes and exercise of the Warrants), after notice duly given by the Company to each Investor.
		

		
			
		

		
			

		 

		

			6

		

 

 
		

		
			(e)Benefits of the Agreement.  The terms and conditions of this Agreement shall inure to the benefit of and be binding upon the respective permitted successors and assigns of the parties.  Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their respective successors and assigns any rights, remedies, obligations, or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement.
		

		
			 
		

		
			(f)Counterparts.  This Agreement may be executed in one or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.  A signature to this Agreement transmitted electronically shall have the same authority, effect and enforceability as an original signature.
		

		
			 
		

		
			(g)Titles and Subtitles.  The titles and subtitles used in this Agreement are used for convenience only and are not to be considered in construing or interpreting this Agreement.
		

		
			 
		

		
			(h)Severability.  Any provision of this Agreement that is prohibited or unenforceable in any jurisdiction shall, as to such jurisdiction, be ineffective to the extent of such prohibition or unenforceability without invalidating the remaining provisions hereof but shall be interpreted as if it were written so as to be enforceable to the maximum extent permitted by applicable law, and any such prohibition or unenforceability in any jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction.  To the extent permitted by applicable law, the parties hereby waive any provision of law which renders any provisions hereof prohibited or unenforceable in any respect.
		

		
			 
		

		
			(i)Further Assurances.  The parties shall execute and deliver all such further instruments and documents and take all such other actions as may reasonably be required to carry out the transactions contemplated hereby and to evidence the fulfillment of the agreements herein contained.
		

		
			 
		

		
			(j)Entire Agreement.  This Agreement is intended by the parties as a final expression of their agreement and intended to be a complete and exclusive statement of the agreement and understanding of the parties hereto in respect of the subject matter contained herein.  This Agreement supersedes all prior agreements and understandings between the parties with respect to such subject matter.
		

		
			 
		

		
			(k)Governing Law; Consent to Jurisdiction; Waiver of Jury Trial.  This Agreement shall be governed by, and construed in accordance with, the internal laws of the State of New York without regard to the choice of law principles thereof.  Each of the parties hereto irrevocably submits to the exclusive jurisdiction of the courts of the State of New York located in New York County and the United States District Court for the Southern District of New York for the purpose of any suit, action, proceeding or judgment relating to or arising out of this Agreement and the transactions contemplated hereby.  Service of process in connection with any such suit, action or proceeding may be served on each party hereto anywhere in the world by the same methods as are specified for the giving of notices under this Agreement.  Each party hereto irrevocably waives any objection to the laying of venue of any such suit, action or proceeding brought in such courts and irrevocably waives any claim that any such suit, action or proceeding brought in any such court has been brought in an inconvenient forum.   EACH OF THE PARTIES HERETO WAIVES ANY RIGHT TO REQUEST A TRIAL BY JURY IN ANY LITIGATION WITH RESPECT TO THIS AGREEMENT AND REPRESENTS THAT COUNSEL HAS BEEN CONSULTED SPECIFICALLY AS TO THIS WAIVER.
		

		
			 
		

		
			[signature pages follows]
		

		
			 
		

		
			 
		

		
			

		 

		

			7

		

 

 
		

		
			IN WITNESS WHEREOF, the parties have executed this Agreement or caused their duly authorized officers to execute this Agreement as of the date first above written.
		

		
			 
		

			
					
						 

					
					
						THE COMPANY:

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						PURE BIOSCIENCE, INC.

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						By:

					
					
						/s/ Hank Lambert

				
	
					
						 

					
					
						Name:

					
					
						Hank Lambert

				
	
					
						 

					
					
						Title:

					
					
						Chief Executive Officer

				

		
			 
		

		
			 
		

		
			
		

		
			

		 

		

			 

		

 

 
		

		
			 
		

		
			IN WITNESS WHEREOF, the parties have executed this Agreement or caused their duly authorized officers to execute this Agreement as of the date first above written.
		

		
			 
		

			
					
						 

					
					
						THE INVESTORS:

				
	
					
						 

					
					
						 

				
	
					
						 

					
					
						 

				
	
					
						 

					
					
						By:

					
					
						/s/ John P. Pfannenbecker

				
	
					
						 

					
					
						Printed Name:

					
					
						John P. Pfannenbecker

				
	
					
						 

					
					
						Title (if applicable):

					
					
						Manager

				
	
					
						 

					
					
						Entity Name (if applicable):

					
					
						Franchise Brands, LLC

				

		
			 
		

		
			
		

		
			

		 

		

			 

		

 

Exhibit A
		

		
			 
		

		
			Plan of Distribution
		

		
			 
		

		
			The selling stockholders, which includes donees, pledgees, transferees or other successors-in-interest selling shares of common stock or interests in shares of common stock received after the date of this prospectus from a selling stockholder as a gift, pledge, partnership distribution or other transfer, may, from time to time, sell, transfer or otherwise dispose of any or all of their shares of common stock or interests in shares of common stock on any stock exchange, market or trading facility on which the shares are traded or in private transactions.  These dispositions may be at fixed prices, at prevailing market prices at the time of sale, at prices related to the prevailing market price, at varying prices determined at the time of sale, or at negotiated prices.
		

		
			 
		

		
			The selling stockholders may use any one or more of the following methods when disposing of shares or interests therein:
		

		
			 
		

			
	
			
				 ·
			

			
	
			
			ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;

		
			 
		

			
	
			
				 ·
			

			
	
			
			block trades in which the broker-dealer will attempt to sell the shares as agent, but may position and resell a portion of the block as principal to facilitate the transaction;

		
			 
		

			
	
			
				 ·
			

			
	
			
			purchases by a broker-dealer as principal and resale by the broker-dealer for its account;

		
			 
		

			
	
			
				 ·
			

			
	
			
			an exchange distribution in accordance with the rules of the applicable exchange;

		
			 
		

			
	
			
				 ·
			

			
	
			
			privately negotiated transactions;

		
			 
		

			
	
			
				 ·
			

			
	
			
			short sales effected after the date the registration statement of which this prospectus is a part is declared effective by the SEC;

		
			 
		

			
	
			
				 ·
			

			
	
			
			through the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise;

		
			 
		

			
	
			
				 ·
			

			
	
			
			broker-dealers may agree with the selling stockholders to sell a specified number of such shares at a stipulated price per share;

		
			 
		

			
	
			
				 ·
			

			
	
			
			a combination of any such methods of sale; and

		
			 
		

			
	
			
				 ·
			

			
	
			
			any other method permitted by law.

		
			 
		

		
			The selling stockholders may, from time to time, pledge or grant a security interest in some or all of the shares of common stock owned by them and, if they default in the performance of their secured obligations, the pledgees or secured parties may offer and sell the shares of common stock, from time to time, under this prospectus, or under an amendment to this prospectus under Rule 424(b)(3) or other applicable provision of the Securities Act amending the list of selling stockholders to include the pledgee, transferee or other successors in interest as selling stockholders under this prospectus.  The selling stockholders also may transfer the shares of common stock in other circumstances, in which case the transferees, pledgees or other successors in interest will be the selling beneficial owners for purposes of this prospectus.
		

		
			  
		

		
			In connection with the sale of our common stock or interests therein, the selling stockholders may enter into hedging transactions with broker-dealers or other financial institutions, which may in turn engage in short sales of the common stock in the course of hedging the positions they assume.  The selling stockholders may also sell shares of our common stock short and deliver these securities to close out their short positions, or loan or pledge the common stock to broker-dealers that in turn may sell these securities.  The selling stockholders may also enter into option or other transactions with broker-dealers or other financial institutions or the creation of one or more derivative securities which require the delivery to such broker-dealer or other financial institution of shares offered by this
		

		
			
		

		
			

		 

		

			 

		

 

 
		

		
			prospectus, which shares such broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction).
		

		
			 
		

		
			The aggregate proceeds to the selling stockholders from the sale of the common stock offered by them will be the purchase price of the common stock less discounts or commissions, if any.  Each of the selling stockholders reserves the right to accept and, together with their agents from time to time, to reject, in whole or in part, any proposed purchase of common stock to be made directly or through agents.  We will not receive any of the proceeds from this offering. Upon any exercise of the warrants by payment of cash, however, we will receive the exercise price of the warrants.
		

		
			 
		

		
			The selling stockholders also may resell all or a portion of the shares in open market transactions in reliance upon Rule 144 under the Securities Act of 1933, provided that they meet the criteria and conform to the requirements of that rule.
		

		
			 
		

		
			The selling stockholders and any underwriters, broker-dealers or agents that participate in the sale of the common stock or interests therein may be “underwriters” within the meaning of Section 2(11) of the Securities Act.  Any discounts, commissions, concessions or profit they earn on any resale of the shares may be underwriting discounts and commissions under the Securities Act.  Selling stockholders will be subject to the prospectus delivery requirements of the Securities Act, unless an exemption therefrom is available.
		

		
			 
		

		
			To the extent required, the shares of our common stock to be sold, the names of the selling stockholders, the respective purchase prices and public offering prices, the names of any agents, dealer or underwriter, any applicable commissions or discounts with respect to a particular offer will be set forth in an accompanying prospectus supplement or, if appropriate, a post-effective amendment to the registration statement that includes this prospectus.
		

		
			 
		

		
			In order to comply with the securities laws of some states, if applicable, the common stock may be sold in these jurisdictions only through registered or licensed brokers or dealers.  In addition, in some states the common stock may not be sold unless it has been registered or qualified for sale or an exemption from registration or qualification requirements is available and is complied with.
		

		
			 
		

		
			 There can be no assurance that any selling shareholder will sell any or all of the shares of common stock registered pursuant to the shelf registration statement, of which this prospectus forms a part.
		

		
			 
		

		
			We have advised the selling stockholders that the anti-manipulation rules of Regulation M under the Exchange Act may apply to sales of shares in the market and to the activities of the selling stockholders and their affiliates.  In addition, to the extent applicable we will make copies of this prospectus (as it may be supplemented or amended from time to time) available to the selling stockholders for the purpose of satisfying the prospectus delivery requirements of the Securities Act.  The selling stockholders may indemnify any broker-dealer that participates in transactions involving the sale of the shares against certain liabilities, including liabilities arising under the Securities Act.
		

		
			 
		

		
			We have agreed to indemnify the selling stockholders against liabilities, including liabilities under the Securities Act and state securities laws, relating to the registration of the shares offered by this prospectus.
		

		
			 
		

		
			We will pay all expenses of the registration of the shares of common stock pursuant to the registration rights agreement, estimated to be $35,000 in total, including, without limitation, Securities and Exchange Commission filing fees and expenses of compliance with state securities or “blue sky” laws and the selling stockholders’ expenses; provided, however, that a selling shareholder will pay all underwriting discounts and selling commissions, if any.
		

		
			 
		

		
			We have agreed with the selling stockholders to keep the registration statement of which this prospectus constitutes a part effective until the earlier of (1) such time as all of the shares covered by this prospectus have been disposed of pursuant to and in accordance with the registration statement or (2) the date on which the shares may be sold pursuant to Rule 144 of the Securities Act without regard to any volume limitation requirements under Rule 144 of the Securities Act.
		

		
			 
		

		
			
		

		
			

		 

		

			 

		

 

 
		

		
			Exhibit B
		

		
			 
		

		
			SELLING SHAREHOLDERS QUESTIONNAIRE
		

		
			 
		

		
			In connection with the preparation of the Registration Statement of Pure Bioscience, Inc. (the “Company”), it is necessary that the Company obtain from you (“Selling Shareholder”) written verification of certain information required to be disclosed in the Registration Statement.
		

		
			 
		

		
			Please use the utmost care in responding to this Questionnaire.  You should be aware that if the Registration Statement contains any false or misleading statements which are material, under certain circumstances the Company and those in control of the Company, including officers and directors, could be subject to liability.   If the answer to any of the questions is “no,” “none” or “not applicable,” please so indicate.  Please do not leave any questions unanswered  .
		

		
			 
		

		
			As used herein, “Fiscal Year” refers to the Company’s fiscal year ended July 31, 2015, and for previous fiscal years.  Other  italicized  terms are defined in Appendix A  to this Questionnaire.
		

		
			 
		

		
			If at any time prior to the effectiveness of the Registration Statement you discover that your answer to any question was inaccurate, or if any event occurring subsequent to your completion hereof and prior to the effectiveness of the Registration Statement would require a change in your answers to any questions, please contact Mark Elliott,  the Vice President Finance,  by telephone at (619) 596-8600, ext. 116 immediately.
		

		
			 
		

		
			I hereby acknowledge, by my execution and dating of this Questionnaire in the places indicated below, that my answers to the following questions are true and correct to the best of my information and belief.
		

		
			 
		

			
					
						THE INVESTORS:

					
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						 

					
					
						 

					
					
						 

				
	
					
						By:

					
					
						 

					
					
						 

					
					
						Dated:

					
					
						 

				
	
					
						Printed Name:

					
					
						 

					
					
						 

					
					
						 

					
					
						 

				
	
					
						Title (if applicable):

					
					
						 

					
					
						 

					
					
						 

					
					
						 

				
	
					
						Entity Name (if applicable):

					
					
						 

					
					
						 

					
					
						 

					
					
						 

				

		
			 
		

		
			 
		

		
			
		

		
			

		 

		

			 

		

 

 
		

		
			I
		

		
			GENERAL INFORMATION
		

		
			 
		

		
			Question 1(a):
		

		
			 
		

		
			Name:  Please set forth the full name of the Selling Shareholder.
		

		
			 
		

		
			Answer:
		

		
			 
		

		
			 
		

		
			Question 1(b):
		

		
			 
		

		
			If the Selling Shareholder is not a natural person, please indicate whether the Selling Shareholder is one of the following (and circle as appropriate):
		

		
			 
		

			
	
			
				 ·
			

			
	
			
			a reporting company under the Exchange Act

		
			 
		

			
	
			
				 ·
			

			
	
			
			a majority owned subsidiary of a reporting company under the Exchange Act,

		
			 
		

			
	
			
				 ·
			

			
	
			
			a registered investment fund under the 1940 Act.

		
			 
		

		
			Yes ___________     No ____________
		

		
			 
		

		
			Question 1(c):
		

		
			 
		

		
			If the Selling Shareholder is not one of the three above, identify those persons that have voting and investment control over the Company.
		

		
			 
		

		
			Answer:
		

		
			 
		

		
			 
		

		
			Question 1(d):
		

		
			 
		

		
			Is the Selling Shareholder an executive officer or director of the Company or 5% or more holder of Company shares of common stock.
		

		
			 
		

		
			Yes ____________    No ______________
		

		
			 
		

		
			Question 2:
		

		
			 
		

		
			Family Relationships.  If you have any family relationship, by blood, marriage or adoption not more remote than first cousin, with any director, executive officer , or nominee to become a director or executive  officer  of the Company, its parent, any of its subsidiaries, or other  affiliates , or any individual who has been employed by the Company in the past three years as an  executive officer , please identify such relative and describe the nature of the relationship.
		

		
			 
		

		
			Answer:
		

		
			 
		

		
			 
		

		
			Question 3:
		

		
			 
		

		
			Is the Selling Shareholder a broker dealer and/or member of the Financial Industry Regulatory Authority (“FINRA”) or a broker dealer’s affiliate and/or member of FINRA?
		

		
			 
		

		
			Yes ___             No ___
		

		
			
		

		
			

		 

		

			 

		

 

 
		

		
			If a Selling Shareholder is a broker dealer and/or member of the FINRA, please indicate whether the Selling Shareholder acquired its securities as compensation for underwriting activities  or  investment purposes.
		

		
			 
		

		
			Yes ___             No ___
		

		
			 
		

		
			If a Selling Shareholder is an affiliate of a broker dealer and/or member of the FINRA, please indicate whether this broker dealer’s affiliate (and circle as appropriate):
		

		
			 
		

			
	
			
				 ·
			

			
	
			
			purchased the securities to be resold in the ordinary course of business; and

		
			 
		

			
	
			
				 ·
			

			
	
			
			had no agreements or understandings, directly or indirectly, with any person to distribute the securities at the time of their purchase.

		
			 
		

		
			Yes ___             No ___
		

		
			 
		

		
			Is any member of your Immediate Family (by blood, marriage or adoption) a member of the FINRA.
		

		
			 
		

		
			Yes ___             No ___
		

		
			 
		

		
			If you marked “Yes” to any of the questions above, please briefly describe the facts below, giving the names of the broker dealer and/or member of the FINRA to which your answer refers (including, for example, percentage of ownership, amount of loan and interest payable, applicable dates, names of Affiliates, family, etc).
		

		
			 
		

			
					
						 

				
	
					
						 

				
	
					
						 

				
	
					
						 

				

		
			 
		

		
			Question 4:
		

		
			 
		

		
			State whether you provide any consulting or other services to the Company.
		

		
			 
		

		
			Yes ___             No ___
		

		
			 
		

		
			 
		

		
			(a)           If you marked “Yes”, please briefly describe such services, including cash and non-cash compensation received and attach copies of written agreements or correspondence describing such services.
		

		
			 
		

			
					
						 

				
	
					
						 

				
	
					
						 

				
	
					
						 

				

		
			 
		

		
			
		

		
			

		 

		

			 

		

 

 
		

		
			(b)           Please identify any of the following relationships you have with any Member of the FINRA.
		

		
			 
		

			
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						None

					
					
						☐

				
	
					
						 

					
					
						Advisor

					
					
						☐

				
	
					
						 

					
					
						Officer

					
					
						☐

				
	
					
						 

					
					
						Director

					
					
						☐

				
	
					
						 

					
					
						Trustee

					
					
						☐

				
	
					
						 

					
					
						Founder

					
					
						☐

				
	
					
						 

					
					
						Registered Representative

					
					
						☐

				
	
					
						 

					
					
						5% Stockholder

					
					
						☐

				
	
					
						 

					
					
						Employee

					
					
						☐

				
	
					
						 

					
					
						Immediate Family

					
					
						☐

				
	
					
						 

					
					
						Broker/Dealer

					
					
						☐

				
	
					
						 

					
					
						Promoter

					
					
						☐

				
	
					
						 

					
					
						Consultant

					
					
						☐

				
	
					
						 

					
					
						Finder

					
					
						☐

				
	
					
						 

					
					
						Bridge Lender

					
					
						☐

				
	
					
						 

					
					
						General Partner

					
					
						☐

				
	
					
						 

					
					
						Limited Partner

					
					
						☐

				
	
					
						 

					
					
						Equity Investor

					
					
						☐

				
	
					
						 

					
					
						Client or Customer

					
					
						☐

				
	
					
						 

					
					
						Subordinated Debt Holder

					
					
						☐

				
	
					
						 

					
					
						Other

					
					
						☐

				

		
			 
		

		
			(c)           Please describe the nature of any relationship identified above.  For example, if you are an advisor, promoter, consultant or finder, describe the compensation you received; if you are an equity investor, state the class of securities and percentage interest you hold; and if you are an Immediate Family Member, describe the exact relationship, including the name of the person  to whom you are related and the position such  person  holds with any Member of the FINRA.  Identify the Member of the FINRA:
		

		
			 
		

			
					
						 

				
	
					
						 

				
	
					
						 

				
	
					
						 

				

		
			 
		

		
			 
		

		
			(d)           State whether you have any oral and/or written agreements with any Member of the FINRA or person associated  with a Member of FINRA concerning the disposition of your securities of the Company.
		

		
			 
		

		
			Yes ___             No ___
		

		
			 
		

		
			(e)           If you marked “Yes,” please briefly describe such agreement and attach copies of written agreements or correspondence describing such arrangement.
		

		
			 
		

			
					
						 

				
	
					
						 

				
	
					
						 

				
	
					
						 

				

		
			 
		

		
			
		

		
			

		 

		

			 

		

 

Question 5:
		

		
			 
		

		
			Involvement in Certain Legal Proceedings.  Have any of the following events occurred during the last five years:
		

		
			 
		

		
			(a)           Were you the subject of any order, judgment or decree of any court (not subsequently reversed, suspended or vacated by any court) permanently or temporarily enjoining you (i) from acting as a futures commission merchant, introducing broker, commodity trading advisor, commodity pool operator, floor broker, leverage transaction merchant, any other  person regulated by the Commodity Futures Trading Commission (“CFTC ”), or an  associated person  of any of the foregoing; or as an investment advisor, underwriter, broker or dealer in securities; or as an affiliated  person , director or employee of any investment company, bank, savings and loan association or insurance company; or from engaging in or continuing any conduct or practice in connection with such activity; or (ii) from engaging in any type of business practice; or (iii) from engaging in any activity in connection with the purchase or sale of any security or commodity or in connection with any violation of federal or state securities laws or federal commodities laws?
		

		
			 
		

		
			Yes ___             No ___
		

		
			 
		

		
			
		

		
			

		 

		

			 

		

 

 
		

		
			(b)           Were you the subject of any order, judgment or decree of any federal or state authority barring, suspending or otherwise limiting for more than 60 days your right to engage in any activity described in subparagraph (a) above, or to be associated with  persons  engaged in any such activity?
		

		
			 
		

		
			Yes ___             No ___
		

		
			 
		

		
			(c)           Has any court, the SEC, CFTC, FINRA or any securities exchange or commodity exchange imposed a sanction against you or found you to have violated any federal or state securities or commodities laws?
		

		
			 
		

		
			Yes ___             No ___
		

		
			 
		

		
			(d)           Do you or any of your associates have any claims against the Company or any of its subsidiaries; or are you or any of your associates a party adverse to the Company or any of its subsidiaries in any legal proceeding; or do you or any of your associates have a material interest adverse to the Company or any of its subsidiaries in any legal proceeding?
		

		
			 
		

		
			Yes ___             No ___
		

		
			 
		

		
			II
		

		
			SECURITY OWNERSHIP
		

		
			 
		

		
			Question 6: Your Securities Holdings.
		

		
			 
		

		
			(a)           As to each class of equity securities of the Company, its parent or any subsidiary, state the total number of shares or other units  beneficially owned  by you as of the date hereof.
		

		
			 
		

			
					
						Title of Equity Security

					
						(include warrants, options and convertible debt)

					
					
						 

					
					
						Number of Shares

					
						Beneficially Owned

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						 

					
					
						 

				

		
			 
		

		
			If you listed any warrants, options, convertible debt or other derivative securities that are not fully vested, please set forth the vesting schedule below.
		

		
			 
		

		
			Vesting Schedule(s):
		

		
			 
		

		
			(b)           If, as a result of applying the rules regarding beneficial ownership summarized in the Appendix to this Questionnaire, you have included in the amount stated in answer to  Question 6(a)  above under “Number of Shares Beneficially Owned” shares not issued in your name, please provide details as to the nature of such beneficial ownership of such shares or other units and state the amount of shares or units so owned;
		

		
			 
		

		
			
		

		
			

		 

		

			 

		

 

Answer:
		

		
			 
		

		
			(c)           If, as a result of applying the rules regarding beneficial ownership summarized in the Appendix to this Questionnaire, you have excluded from the amount stated in the answer to  Question 6(a)  above under “Number of Shares Beneficially Owned” shares or units which are issued in your name, please state the amount so excluded and explain why you are not the beneficial owner of such shares or units.
		

		
			 
		

		
			Answer:
		

		
			 
		

		
			(d)           Of the total number of shares or units beneficially owned by you, as reported in answer to Question 6(a), indicate below the amounts as to which you have sole or shared voting or investment power.
		

		
			 
		

			
					
						 

					
					
						Common Stock

					
					
						 

					
					
						Other

					
						(i.e., warrants, options or

					
						convertible debt)

				
	
					
						Sole voting power

					
					
						 

					
					
						 

					
					
						 

				
	
					
						Shared voting power

					
					
						 

					
					
						 

					
					
						 

				
	
					
						Sole investment power

					
					
						 

					
					
						 

					
					
						 

				
	
					
						Shared investment power

					
					
						 

					
					
						 

					
					
						 

				

		
			 
		

		
			 
		

		
			(e)           Does the Selling Shareholder have a registration rights agreement with the Company other than as described in the Purchase Agreement entered into in connection with this questionnaire?
		

		
			 
		

		
			Yes ___             No ___
		

		
			 
		

		
			If so, attach a copy.
		

		
			 
		

		
			Question 7:  Disclaimer of Beneficial Ownership.
		

		
			 
		

		
			(a)           If you wish to disclaim beneficial ownership of any securities referred to above, please set forth the number of such shares or units, the circumstances upon which the disclaimer of  beneficial ownership  is based, the name of the  person  or persons  who should be shown as the beneficial owner(s) of such shares or units, and your relationship to that  person or those persons.
		

		
			 
		

		
			Answer:
		

		
			 
		

		
			(b)           Do you or any of your affiliates or associates participate in investment decisions made by any nonprofit entity that owns Company securities? If yes, please provide details and indicate whether you disclaim beneficial ownership  of such Company securities.
		

		
			 
		

		
			Yes ___             No ___
		

		
			 
		

		
			Question 8:
		

		
			 
		

		
			Securities Holdings of Your Relatives.  If any equity securities of the Company, its parent or any subsidiary are beneficially owned by any relative of yours (by blood, marriage or adoption) who shares your home, please indicate below the name of each such relative, your relationship with him or her, and the amount of shares so owned.
		

		
			 
		

		
			Answer:
		

		
			 
		

		
			
		

		
			

		 

		

			 

		

 

III
		

		
			CERTAIN TRANSACTIONS AND RELATIONSHIPS
		

		
			 
		

		
			Question 9:
		

		
			 
		

		
			Transactions with Management.  In the table on the following page, describe any transaction (or series of similar transactions), during the Company’s last three Fiscal Years, or any currently proposed transaction  (or series of similar transactions), to which the Company or any of its subsidiaries was or is to be a party, and in which you had or anyone in your immediate family has, a material direct or indirect financial interest.  Identify the person (s) involved and state the nature of your or their interest in the transaction, the amount of the  transaction  and the amount of your or their interest in the  transaction . (Attach a supplemental page if necessary.)
		

		
			 
		

			
					
						Description of

					
						Transaction

					
					
						 

					
					
						Persons Involved

					
					
						 

					
					
						Nature of

					
						Interest

					
					
						 

					
					
						Amount of

					
						Transaction

					
					
						 

					
					
						Amount of

					
						Interest

				
	
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						 

				

		
			 
		

		
			Question 10:
		

		
			 
		

		
			Indebtedness of Management. If you or any associate of yours has been indebted to the Company or any of its subsidiaries at any time during the Company’s last three Fiscal Years, state: (a) the name of the indebted person ; (b) if the indebted  person  is an  associate , the nature of your relationship to that  person ; (c) the largest aggregate amount of indebtedness outstanding at any time during the Company’s last three Fiscal Years; (d) the nature of the indebtedness and of the transaction in which it was incurred; (e) the amount of indebtedness outstanding as of the latest practicable date (indicating that date); and (f) the rate of interest paid or charged thereon, if any.
		

		
			 
		

		
			Include (with respect to yourself only) any instances where the Company, either directly or indirectly (including through a subsidiary), extended or maintained credit for you, arranged for the extension of credit, or renewed any extension of credit, in the form of a personal loan to or for you.
		

		
			 
		

		
			Answer:
		

		
			 
		

		
			
		

		
			

		 

		

			 

		

 

 
		

		
			APPENDIX A
		

		
			 
		

		
			DEFINITIONS OF CERTAIN TERMS
		

		
			IN SELLING SHAREHOLDERS QUESTIONNAIRE
		

		
			(Arranged Alphabetically)
		

		
			 
		

		
			1.  “Affiliate.”  An “affiliate” of any entity is a person that, directly or indirectly, through one or more intermediaries, controls, is  controlled  by or is under common  control  with such  person  (for example, a parent subsidiary or sister corporation).
		

		
			 
		

		
			2.  “Associate.”  “Associate” for the purpose of Question 4 means (1) any corporation or organization (other than the Company or a majority-owned subsidiary of the Company) of which you are an officer  or partner or are, directly or indirectly, the beneficial owner of 10% or more of any class of equity securities; (2) any trust or other estate in which you have a substantial beneficial interest or as to which you serve as a trustee or in a similar fiduciary capacity; and (3) any member of your  immediate family .  ”Associate” for the purpose of Question 13 means the same as the foregoing, except that subsection (1) shall state “any corporation or organization ... of which you are an  executive officer.”
		

		
			 
		

		
			3.  “Beneficially Owned” or “Beneficial Ownership.”
		

		
			 
		

		
			a.  General Rule. Under the rules of the SEC, you are deemed to “beneficially own” or be the “beneficial owner” of any security with respect to which you have or share, directly or indirectly, through any contract, arrangement, understanding, relationship, agreement or otherwise: (1) Voting Power (which includes the power to vote, or to direct the voting of, such security); and/or (2) Investment Power (which includes the power to dispose, or to direct the disposition of, such security). You are also the beneficial owner of a security if you, directly or indirectly, create or use a trust, proxy, power of attorney, pooling arrangement or any other contract, arrangement, or device with the purpose or effect of divesting yourself of beneficial ownership of a security or preventing the vesting of such beneficial ownership.
		

		
			 
		

		
			Some specific applications of the above definition of beneficial ownership are:
		

		
			 
		

		
			(i)  Family situations. Although the determination of beneficial ownership of securities is necessarily a question to be determined in light of the facts of each particular case, family relationships may result in your having, or sharing, the power to vote, or direct the voting of, or dispose, or direct the disposition of, shares held by your family members. In view of the broad definition of “Beneficial Ownership,” it may be prudent to include such shares in your beneficial ownership disclosure and then disclaim beneficial ownership of such securities pursuant to Question 6.
		

		
			 
		

		
			(ii)  Shares held by others for your benefit. There are numerous instances in which you may have, or share, voting or investment power (as defined above) over securities, although the securities are held by another  person or entity. For example, you may have or share such power in securities held for you or your family members living with you by custodians, brokers, relatives, executors, administrators or trustees; securities held for your account by pledgees; securities owned by a partnership in which you are a member; and securities owned by a corporation which is or should be regarded as a personal holding company of yours or is controlled by you.
		

		
			 
		

		
			(iii)  Shares held by you for the benefit of others. Beneficial ownership of securities also includes securities held in your name as a trustee, custodian or other fiduciary where you have, or share, voting or investment power with respect to such securities.
		

		
			 
		

		
			b.  Options and other rights to acquire securities. In addition to being beneficial owner of securities over which you have, or share, voting or investment power, the SEC has determined that you are deemed to be the beneficial owner of a security if you have a right to acquire beneficial ownership of (i.e., the right to obtain or share voting or investment power over) such security at any time within sixty days. Examples of such rights would include the right to acquire: (i) through the exercise of any option, warrant or similar right; (ii) through conversion of any security; or (iii) pursuant to the power to revoke, or the provision for automatic termination of, a trust, discretionary
		

		
			
		

		
			

		 

		

			 

		

 

 
		

		
			account or similar arrangement. Also, if you have acquired or hold any options, convertible securities or power to revoke such a trust with the “purpose or effect” of changing or influencing control of the Company, you are deemed the beneficial owner of the underlying securities upon such acquisition, without regard to the sixty-day rule stated above.
		

		
			 
		

		
			4.  “Control” or “Controlled.”  The term “control” means the possession, direct or indirect, of the power to direct or cause the direction of the management and policies of the Company, whether through the ownership of voting securities, by contract or otherwise. An executive officer  or director of a company generally is considered to control that company. It is suggested that, if you are in doubt as to the meaning of “control” in a particular context, you communicate with counsel.
		

		
			 
		

		
			5.  “Equity Security.”  The definition of “equity security” encompasses more than common and preferred stock. It includes for instance convertible debt instruments as well as warrants and options to acquire stock or similar securities. If you have a question as to the proper characterization of your holdings you should consult with the Company’s legal counsel.
		

		
			 
		

		
			6.  “Executive Officer.”  “Executive officer” for the purpose of this Questionnaire means the president of a company, any vice president of it in charge of a principal business unit, division or function (such as sales, administration or finance), any other officer who performs a policy-making function or any other  person  who performs similar policy-making functions for the company. Executive officers of subsidiaries may be deemed executive officers of a company if they perform such policy-making functions for the company.
		

		
			 
		

		
			7.  “Immediate Family.”  “Immediate family” for the purpose of this Questionnaire includes your spouse, parents, children, siblings, mothers-and fathers-in-law, sons- and daughters-in-law, and brothers- and sisters-in-law.
		

		
			 
		

		
			8.  “Officer.”  “Officer” means a president, vice president, secretary, treasurer or principal financial officer, comptroller or principal accounting officer, and any person routinely performing corresponding functions with respect to any organization whether incorporated or unincorporated.
		

		
			 
		

		
			9.  “Person.”  “Person” for the purpose of this Questionnaire means an individual, a corporation, a partnership, an association, a joint-stock company, a business trust, an unincorporated organization, or any other entity.
		

		
			 
		

		
			10.  “Transaction” or “Transactions.”  “Transaction” or “transactions” is to be understood in its broadest sense, and includes the direct or indirect receipt of anything of value. No transaction or interest therein need be disclosed where: (a) the rates or charges involved in the transaction are determined by competitive bids, or the transaction involves the rendering of services as a common or contract carrier or public utility at rates or charges fixed in conformity with law or governmental authority; (b) the transaction involves services as a bank depository of funds, transfer agent, registrar, trustee under a trust indenture or similar services; or (c) the interest in question arises solely from the ownership of securities of the Company and the interested party receives no extra or special benefit not shared on a pro-rata basis by all shareholders.pure_Ex_10_32

		
			Exhibit 10.32
		

		
			 
		

		
			PURE Bioscience, Inc.
		

		
			 
		

		
			RESTRICTED STOCK UNITS AGREEMENT
		

		
			(Executive Officer)
		

		
			 
		

		
			THIS RESTRICTED STOCK UNITS AGREEMENT (the “Agreement”) is made and entered into as of the _____ day of ______ (the “Grant Date”), by and between PURE BIOSCIENCE, INC., a Delaware corporation, and _____________ (the “Grantee”), an executive officer of the Company. The Company has granted to the Grantee an award (the “Award”) consisting of __________  (_____) Restricted Stock Units (the “Total Number of Units”), subject to the terms and conditions of this Agreement.  Each Unit represents a right to receive upon settlement one (1) share of Stock. The Award has not been granted pursuant to any compensatory, bonus, or similar plan maintained or otherwise sponsored by the Company (collectively, the “Plan”), and the shares of Stock that may become issuable upon settlement the Units shall not reduce the number of shares of Stock available for issuance under any Plan.
		

		
			 
		

		
			1.DEFINITIONS AND CONSTRUCTION.
		

		
			 
		

		
			1.1Definitions.  Capitalized terms used herein shall have the following meanings.
		

		
			 
		

		
			(a)“Board” means the Board of Directors of the Company. If one or more committees of the Board of Directors have been appointed by the Board to administer this Agreement, “Board” also means such committee(s).
		

		
			 
		

		
			(b)“Cause” shall have the same meaning as under Section 4.3(b) of the Employment Agreement executed by and between the parties hereto and to which this Agreement is attached as Exhibit A (the “Employment Agreement”). 
		

		
			 
		

		
			(c)“Change in Control” shall have the same meaning as under Section 5.2 of the Employment Agreement.
		

		
			 
		

		
			(d)“Code” means the Internal Revenue Code of 1986, as amended, and any applicable regulations and administrative guidelines promulgated thereunder.
		

		
			 
		

		
			(e)“Company” means PURE Bioscience, Inc., a Delaware corporation, and any successor thereto.
		

		
			 
		

		
			(f)“Complete Disability” shall have the same meaning as under Section 4.3(c) of the Employment Agreement. 
		

		
			 
		

		
			(g)“Dividend Equivalent Units” mean additional Restricted Stock Units credited pursuant to Section 2.3.
		

		
			 
		

		
			(h)“Exchange Act” means the Securities Exchange Act of 1934, as amended.
		

		
			 
		

		
			(i)“Expiration Date” means the seventh (7th) anniversary of the Grant Date.
		

		
			 
		

		
			(j)“Fair Market Value” means as of any date, the value of a share of Stock or other property as determined by the Board, in its discretion, or by the Company, in its discretion, if such determination is expressly allocated to the Company herein, subject to the following:
		

		
			 
		

		
			(i)If, on such date, the Stock is listed or quoted on a national or regional securities exchange or quotation system, the Fair Market Value of a share of Stock shall be the closing price of a share of Stock as quoted on the national or regional securities exchange or quotation system constituting the 
		

		
			 
		

		
			 
		

		 

		

			1

		

 

		
			primary market for the Stock, as reported in The Wall Street Journal or such other source as the Board deems reliable. If the relevant date does not fall on a day on which the Stock has traded on such securities exchange or quotation system, the date on which the Fair Market Value shall be established shall be the last day on which the Stock was so traded or quoted prior to the relevant date, or such other appropriate day as shall be determined by the Board, in its discretion.
		

		
			 
		

		
			(ii)If, on such date, the Stock is not listed or quoted on a national or regional securities exchange or quotation system, the Fair Market Value of a share of Stock shall be as determined by the Board in good faith without regard to any restriction other than a restriction which, by its terms, will never lapse.
		

		
			 
		

		
			(k)“Good Reason” shall have the same meaning as under Section 4.3(a) of the Employment Agreement.
		

		
			 
		

		
			(l)“Participating Company” means the Company and any subsidiary of the Company.
		

		
			 
		

		
			(m)“Restricted Stock Unit” or “Unit” means a right to receive on the applicable Settlement Date and in accordance with this Agreement one (1) share of Stock, and includes the Total Number of Units originally granted pursuant to this Agreement and the Dividend Equivalent Units credited pursuant to Section 2.3, as both may be adjusted from time to time pursuant to Section  7.
		

		
			 
		

		
			(n)“Securities Act” means the Securities Act of 1933, as amended.
		

		
			 
		

		
			(o)“Service” means the Grantee’s service to the Company as an employee, director or consultant. The Grantee’s Service shall not be deemed to have been interrupted or terminated if the Grantee takes any sick leave, or other bona fide leave of absence approved by the Company’s Board of Directors.
		

		
			 
		

		
			(p)“Service Condition” means the condition to the vesting of the Award. The Service Condition is satisfied based on the duration of the Grantee’s continuous Service from the Grant Date, as provided by Section 3.1.
		

		
			 
		

		
			(q)“Settlement Date” means, for each Vested Unit, the earliest of (i) the six-month anniversary of the date the Service Condition is satisfied with respect to such Vested Unit (or, at the sole discretion of the Board, at such later date during the same calendar year); (ii) the date the Grantee’s Service ceases for any reason and such cessation constitutes a “separation from service” within the meaning of Section 409A of the Code; or (iii) the date of a Change in Control that constitutes a “change in control event” within the meaning of Section 409A of the Code.  Notwithstanding the foregoing, if the Settlement Date is scheduled to occur on a date that is not a business day, the Settlement Date shall instead occur on the next following business day.  In addition, if the Settlement Date does not occur (A) during an “open window period” applicable to the Grantee, as determined by the Company in accordance with its then effective insider trading policy or (B) on a date when the grantee is otherwise permitted to sell shares of Stock on an established stock exchange or quotation system, then the Settlement Date shall be extended to the first business day when the Grantee is not prohibited from selling shares of Stock in the open public market, but in no event later than December 31 of the calendar year in which the Settlement Date was scheduled to occur, or, if and only if, permitted in a manner that complies with Treasury Regulations Section 1.409A-1(b)(4), no later than the date that is the 15th day of the third calendar month of the applicable year following the year in which the shares of Stock subject to this Award are no longer subject to a “substantial risk for forfeiture” within the meaning of Treasury Regulations Section 1.409A-1(d). 
		

		
			 
		

		
			(r)“Stock” means the common stock of the Company, subject to adjustment as provided by Section  7.
		

		
			
		

		 

		

			 

		

 

		
			(s)“Trading Compliance Policy” means the written policy of the Company pertaining to the purchase, sale, transfer or other disposition of the Company’s equity securities by directors, officers, employees or other service providers who may possess material, nonpublic information regarding the Company or its securities.
		

		
			 
		

		
			(t)“Vested Unit” means a Unit that has vested in accordance with Section 3 and ceased to be subject to the Company Reacquisition Right described in Section 4.1.
		

		
			 
		

		
			1.2Construction.  Captions and titles contained herein are for convenience only and shall not affect the meaning or interpretation of any provision of this Agreement. Except when otherwise indicated by the context, the singular shall include the plural and the plural shall include the singular. Use of the term “or” is not intended to be exclusive, unless the context clearly requires otherwise.
		

		
			 
		

		
			2.THE AWARD.
		

		
			 
		

		
			2.1Grant of Units.  On the Grant Date, the Grantee shall acquire, subject to the provisions of this Agreement, the Total Number of Units, subject to adjustment as provided in Section 7. Each Unit represents a right to receive one (1) share of Stock on the applicable Settlement Date and in accordance with this Agreement.
		

		
			 
		

		
			2.2No Monetary Payment Required. The Grantee is not required to make any monetary payment (other than applicable tax withholding, if any) as a condition to receiving the Units or shares of Stock issued upon the vesting or settlement of the Units, the consideration for which shall be services to be rendered to a Participating Company or for its benefit.  Notwithstanding the foregoing, if required by applicable law, the Grantee shall furnish consideration in the form of cash or past services rendered to a Participating Company or for its benefit having a value not less than the par value of the shares of Stock issued upon settlement of the Units.
		

		
			 
		

		
			2.3Dividend Equivalent Units. On the date that the Company pays a cash dividend or other cash distribution to holders of Stock generally, the Grantee shall be credited with a number of additional whole Dividend Equivalent Units determined by dividing (a) the product of (i) the dollar amount of the cash dividend or distribution paid per share of Stock on such date and (ii) the total number of Units previously credited to the Grantee pursuant to this Agreement which have not been settled or forfeited pursuant to the Company Reacquisition Right (as defined below) as of such date, by (b) the Fair Market Value per share of Stock on such date. Any resulting fractional Dividend Equivalent Unit shall be rounded to the nearest whole number. Such additional Dividend Equivalent Units shall be subject to the same terms and conditions and shall be settled or forfeited in the same manner and at the same time as the Units originally subject to this Agreement with respect to which they have been credited.
		

		
			 
		

		
			2.4Termination of the Award. The Award shall terminate upon the first to occur of (a) the final settlement of all Vested Units in accordance with Section 5 (including a final settlement upon the termination or cessation of Grantee’s Services) or (b) the Expiration Date if settlement has not occurred on or before the Expiration Date.
		

		
			 
		

		
			3.VESTING OF UNITS.
		

		
			 
		

		
			3.1Satisfaction of Service Condition. Except as provided by Section 3.2 below and subject to the Grantee’s continuous Service through the applicable date set forth in the table below (each a, “Service Date”), the Service Condition will be satisfied in accordance with the following schedule:
		

		
			 
		

			
					
						Service Date

					
					
						Percentage of Units

				
	
					
						 

					
					
						 

				
	
					
						 

					
					
						 

				
	
					
						 

					
					
						 

				

		
			 
		

		
			
		

		 

		

			 

		

 

		
			3.2[Satisfaction of Performance Condition. Except as provided by Section 3.3 below and subject to the Grantee’s continuous Service through the date of the satisfaction of the applicable Performance Condition, the Performance Condition will be satisfied as follows]:  
		

		
			 
		

			
					
						Percentage of Units

					
					
						Performance Metric

				
	
					
						 

					
					
						 

				
	
					
						 

					
					
						 

				

		
			 
		

		
			3.3Vesting Upon Change in Control or Upon Termination Without Cause or Due to Death, Disability or Good Reason.  Upon the Occurrence of a Change in Control, then the Service Condition will be satisfied with respect to one-hundred percent (100%) of the Total Number of Units that are subject to vesting upon satisfaction of a Service Condition effective as of the date of such Change in Control.  If the Grantee’s Service is involuntarily terminated by the Company for any reason other than Cause or the Grantee’s Service terminates as a result of the Grantee’s death or Disability or Grantee terminates his Service for Good Reason, then the Service Condition will be satisfied with respect to one-hundred percent (100%) of the Total Number of Units that are subject to vesting upon satisfaction of a Service Condition effective as of the date of such termination of Service.
		

		
			 
		

		
			3.4Effect of Termination of Service.  Subject to the vesting provisions in Sections 3.1, and 3.2 above, upon the termination of Grantee’s Service (whether by the Company or by Grantee and whether for Cause or for any or no reason), then:
		

		
			 
		

		
			(a)all Units for which the applicable Service Condition has not been satisfied as of the date of such termination of Service shall be subject to the Company Reacquisition Right (as defined in Section 4.1) immediately upon the termination of Grantee’s Service; and
		

		
			 
		

		
			(b)all Units for which the applicable Service Condition has been satisfied as of the date of such termination of Service (including as a result of Section 3.3) shall not be subject to the Company Reacquisition Right, but instead shall remain Vested Units.  
		

		
			 
		

		
			3.5Payments Upon Vesting.  Upon the Vesting of any Units pursuant to Sections 3.1, or 3.2, above, the Company shall:
		

		
			(a)if Grantee is an employee at the time of Vesting, withhold, on behalf of Grantee, the Federal Insurance Contributions Act tax imposed pursuant to Sections 3101 and 3121(v)(2) of the Code on the Vested Units (the “FICA Amount”).  In addition, the Company shall pay Grantee an amount equal to the sum of (A) the FICA Amount, plus (B) a tax gross-up payment (computed at the highest applicable marginal rate) in an amount that, after payment of all federal, state, and local income and employment taxes, results in the Grantee’s receipt and retention, on an after-tax basis, of an amount equal to all federal, state, and local taxes payable by Grantee on the FICA Amount.
		

		
			(b)if Grantee is a director or consultant at the time of Vesting, pay Grantee an amount equal to the sum of (A) the taxes imposed pursuant to Section 1401 of the Code on the Vested Units that are treated as “self-employment income” (as defined in Section 1402(b) of the Code), plus (B) a tax gross-up payment (computed at the highest applicable marginal rate) in an amount that, after payment of all federal, state, and local income and employment taxes, results in the Grantee’s receipt and retention, on an after-tax basis, of an amount equal to all federal, state, and local taxes payable by Grantee on the amount specified in Section 3.4(b)(A).
		

		
			
		

		
			

		 

		

			 

		

 

The Company shall make any payments due to Grantee pursuant to this Section 3.4 within 24 hours of the Vesting of any Units by wire transfer to the account designated by Grantee.
		

		
			 
		

		
			3.6Federal Excise Tax Under Section 4999 of the Code.
		

		
			 
		

		
			(a)Excess Parachute Payment. If any acceleration of vesting pursuant to the Award and any other payment or benefit (collectively, the “Payments”) received or to be received by the Grantee would, but for this Section, subject the Grantee to any excise tax pursuant to Section 4999 of the Code or any similar or successor provision (the “Excise Tax”) due to the characterization of such acceleration of vesting, payment or benefit as an “excess parachute payment” under Section 280G of the Code, then the aggregate amount of the Payments will be either fully payable or reduced to the largest portion of the Payments that would result in no portion of the Payments (after reduction) being subject to the Excise Tax, whichever results in the Grantee receiving the greatest amount of Payments, on an after-tax basis (accounting for federal, state, and local income taxes and the Excise Tax), even if some or all of the Payments are subject to the Excise Tax.  Any reduction in the Payments required by this Section will be made in the following order: (i) reduction of cash payments; (ii) reduction of accelerated vesting of equity awards other than stock options; (iii) reduction of accelerated vesting of stock options; and (iv) reduction of other benefits paid or provided to the Grantee.  In the event that acceleration of vesting of equity awards is to be reduced, such acceleration of vesting will be cancelled in the reverse order of the date of grant of the Grantee’s equity awards.  If two or more equity awards are granted on the same date, each award will be reduced on a pro-rata basis.
		

		
			 
		

		
			(b)Determination by Tax Firm.  No later than the date of the occurrence of any event that might reasonably be anticipated to result in an “excess parachute payment” to the Grantee, the Company shall request a determination in writing by the professional firm engaged by the Company for general tax purposes, or, if the tax firm so engaged by the Company is serving as accountant or auditor for the acquiror, the Company will appoint a nationally recognized tax firm to make the determinations required by this Section. (the “Tax Firm”).  As soon as practicable thereafter, the Tax Firm shall determine and report to the Company and the Grantee the amount of such acceleration of vesting, payments and benefits to be reduced, if any.  For the purposes of such determination, the Tax Firm may rely on reasonable, good faith interpretations concerning the application of Sections 280G and 4999 of the Code.  The Company and the Grantee shall furnish to the Tax Firm such information and documents as the Tax Firm may reasonably request in order to make its required determination.  The Company shall bear all fees and expenses the Tax Firm charge in connection with its services contemplated by this Section.
		

		
			 
		

		
			4.COMPANY REACQUISITION RIGHT.
		

		
			 
		

		
			4.1Grant of Company Reacquisition Right. In the event that the Grantee’s Service terminates for any reason, the Grantee shall forfeit and the Company shall automatically reacquire all Units for which the applicable Service Condition has not been satisfied as of the time of such termination in accordance with Section 3 (the “Unvested Units”), and the Grantee shall not be entitled to any payment therefor (the “Company Reacquisition Right”).
		

		
			 
		

		
			4.2Dividends, Distributions and Adjustments. Upon the occurrence of a dividend or distribution to the stockholders of the Company paid in shares of Stock or other property, or any other adjustment upon a change in the capital structure of the Company as described in Section 7, any and all new, substituted or additional securities or other property to which the Grantee is entitled by reason of the Grantee’s ownership of Unvested Units shall be immediately subject to the Company Reacquisition Right and included in the terms “Units” and “Unvested Units” for all purposes of the Company Reacquisition Right with the same force and effect as the Unvested Units immediately prior to the dividend, distribution or adjustment, as the case may be.  For purposes of determining the number of Units for which the applicable Service Condition has been satisfied following a dividend, distribution or adjustment, credited Service shall include all Service with any corporation which is a Participating Company at the time the Service is rendered, whether or not such corporation is a Participating Company both before and after any such event.
		

		
			
		

		 

		

			 

		

 

		
			5.SETTLEMENT OF THE UNITS.
		

		
			 
		

		
			5.1Issuance of Shares of Stock. Subject to the provisions of Section 5.3 below, the Company shall issue to the Grantee on the Settlement Date with respect to each Vested Unit to be settled on such date one (1) share of Stock. Shares of Stock issued in settlement of Units are not registered under federal or state securities laws.  
		

		
			 
		

		
			5.2Beneficial Ownership of Shares. A certificate for the shares acquired by the Grantee shall be registered in the name of the Grantee, or, if applicable, in the names of the heirs of the Grantee.
		

		
			 
		

		
			5.3Restrictions on Grant of the Units and Issuance of Shares. As of the date of this Agreement, the grant of the Units and issuance of shares of Stock upon settlement of the Units have not been registered under federal or state securities laws, and as a result, shall be subject to compliance with all applicable requirements of federal, state or foreign law with respect to such securities. No shares of Stock may be issued hereunder if the issuance of such shares would constitute a violation of any applicable federal, state or foreign securities laws or other law or regulations or the requirements of any stock exchange or market system upon which the Stock may then be listed.  The inability of the Company to obtain from any regulatory body having jurisdiction the authority, if any, deemed by the Company’s legal counsel to be necessary to the lawful issuance of any shares subject to this Agreement shall relieve the Company of any liability in respect of the failure to issue such shares as to which such requisite authority shall not have been obtained.  As a condition to the settlement of the Units, the Company may require the Grantee to satisfy any qualifications that may be necessary or appropriate, to evidence compliance with any applicable law or regulation and to make any representation or warranty with respect thereto as may be requested by the Company.
		

		
			 
		

		
			5.4Transfer of Shares.  The Grantee may not transfer the shares of Stock issued upon settlement of the Units except in compliance with applicable federal and state securities laws and the Company’s insider trading policy.
		

		
			5.5Fractional Shares.  The Company shall not be required to issue fractional shares upon the settlement of the Units.
		

		
			 
		

		
			6.TAX WITHHOLDING.
		

		
			 
		

		
			6.1In General. Subject to the obligations of the Participating Company under Sections 3 and  6.2 , at the time this Agreement is executed, or at any time thereafter as requested by a Participating Company, the Grantee hereby authorizes withholding from payroll and any other amounts payable to the Grantee, and otherwise agrees to make adequate provision for, any sums required to satisfy the federal, state, local and foreign tax (including any social insurance) withholding obligations of the Participating Company, if any, which arise in connection with the grant of Units, the vesting of Units or the issuance of shares of Stock in settlement thereof. The Company shall have no obligation to deliver shares of Stock until the tax withholding obligations of the Participating Company have been satisfied by the Grantee.
		

		
			 
		

		
			6.2Assignment of Sale Proceeds. Subject to compliance with applicable law and the Company’s Trading Compliance Policy, if permitted by the Company, the Grantee may satisfy the Participating Company’s tax withholding obligations in accordance with procedures established by the Company providing for delivery by the Grantee to the Company or a broker approved by the Company of properly executed instructions, in a form approved by the Company, providing for the assignment to the Company of the proceeds of a sale with respect to some or all of the shares being acquired upon settlement of Units.
		

		
			 
		

		
			 
		

		
			7.ADJUSTMENTS FOR CHANGES IN CAPITAL STRUCTURE.
		

		
			 
		

		
			Subject to any required action by the stockholders of the Company and the requirements of Section 409A of the Code to the extent applicable, in the event of any change in the Stock effected without
		

		
			
		

		
			

		 

		

			 

		

 

receipt of consideration by the Company, whether through merger, consolidation, reorganization, reincorporation, recapitalization, reclassification, stock dividend, stock split, reverse stock split, split-up, split-off, spin-off, combination of shares, exchange of shares, or similar change in the capital structure of the Company, or in the event of payment of a dividend or distribution to the stockholders of the Company in a form other than Stock (other than regular, periodic cash dividends paid on Stock pursuant to the Company’s dividend policy) that has a material effect on the Fair Market Value of shares of Stock, appropriate and proportionate adjustments shall be made in the number of Units subject to this Agreement and/or the number and kind of shares or other property to be issued in settlement of the Units, in order to prevent dilution or enlargement of the Grantee’s rights under this Agreement.  For purposes of the foregoing, conversion of any convertible securities of the Company shall not be treated as “effected without receipt of consideration by the Company.” Any and all new, substituted or additional securities or other property (other than regular, periodic cash dividends paid on Stock pursuant to the Company’s dividend policy) to which the Grantee is entitled by reason of ownership of Units acquired pursuant to this Agreement will be immediately subject to the provisions of this Agreement on the same basis as all Units originally acquired hereunder. Any fractional Unit or share resulting from an adjustment pursuant to this Section shall be rounded down to the nearest whole number.  Such adjustments shall be determined by the Board, and its determination shall be final, binding and conclusive.
		

		
			 
		

		
			8.RIGHTS AS A STOCKHOLDER OR EMPLOYEE.
		

		
			 
		

		
			The Grantee shall have no rights as a stockholder with respect to any shares which may be issued in settlement of the Units until the date of the issuance of such shares (as evidenced by the appropriate entry on the books of the Company or of a duly authorized transfer agent of the Company).  No adjustment shall be made for dividends, distributions or other rights for which the record date is prior to the date the shares of Stock are issued, except as provided in Section 2.3 or Section  7.  The Grantee understands and acknowledges that the Grantee’s Services to the Company is dictated by the Employment Agreement. Nothing in this Agreement shall confer upon the Grantee any right to continue in the Service of a Participating Company or interfere in any way with any right of a Participating Company to terminate the Grantee’s Service at any time.
		

		
			 
		

		
			9.LEGENDS.
		

		
			 
		

		
			The Company may at any time place legends referencing any applicable federal, state or foreign securities law restrictions on all certificates representing shares of stock issued pursuant to this Agreement.  The Grantee shall, at the request of the Company, promptly present to the Company any and all certificates representing shares acquired pursuant to this Agreement in the possession of the Grantee in order to carry out the provisions of this Section.  Unless otherwise specified by the Company, legends placed on such certificates may include, but shall not be limited to, the following:
		

		
			 
		

		
			“THE SECURITIES EVIDENCED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND MAY NOT BE SOLD, TRANSFERRED, ASSIGNED OR HYPOTHECATED UNLESS THERE IS AN EFFECTIVE REGISTRATION STATEMENT UNDER SUCH ACT COVERING SUCH SECURITIES, THE SALE IS MADE IN ACCORDANCE WITH RULE 144 OR RULE 701 UNDER THE ACT, OR THE COMPANY RECEIVES AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE COMPANY, STATING THAT SUCH SALE, TRANSFER, ASSIGNMENT OR HYPOTHECATION IS EXEMPT FROM THE REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS OF SUCH ACT.”
		

		
			 
		

		
			10.COMPLIANCE WITH SECTION 409A.
		

		
			 
		

		
			It is intended that any election, payment or benefit which is made or provided pursuant to or in connection with this Agreement that may result in or relate to the deferral of compensation within the meaning of Section 409A of the Code (“Section 409A Deferred Compensation”) shall comply in all respects with the
		

		
			
		

		
			

		 

		

			 

		

 

applicable requirements of Section 409A of the Code (including applicable regulations or other administrative guidance thereunder, as determined by the Board in good faith) to avoid the unfavorable tax consequences provided therein for non-compliance.  In connection with effecting such compliance with Section 409A of the Code, the following shall apply:
		

		
			 
		

		
			10.1Separation from Service; Required Delay in Payment to Specified Grantee.  Notwithstanding anything set forth herein to the contrary, no amount payable pursuant to this Agreement on account of the Grantee’s termination of Service which constitutes Section 409A Deferred Compensation shall be paid unless and until the Grantee has incurred a “separation from service” within the meaning of Section 409A of the Code.  Furthermore, to the extent that the Grantee is a “specified employee” within the meaning of the Section 409A as of the date of the Grantee’s separation from service, no amount that constitutes a deferral of compensation which is payable on account of the Grantee’s separation from service shall be paid to the Grantee before the date (the “Delayed Payment Date”) which is first day of the seventh month after the date of the Grantee’s separation from service or, if earlier, the date of the Grantee’s death following such separation from service.  All such amounts that would, but for this Section, become payable prior to the Delayed Payment Date will be accumulated and paid on the Delayed Payment Date.
		

		
			 
		

		
			10.2Other Changes in Time of Payment.  Neither the Grantee nor the Company shall take any action to accelerate or delay the payment of any benefits under this Agreement in any manner which would not be in compliance with Section 409A of the Code.
		

		
			 
		

		
			10.3Amendments to Comply with Section 409A; Indemnification.  Notwithstanding any other provision of this Agreement to the contrary, the Company is authorized to amend this Agreement, to void or amend any election made by the Grantee under this Agreement and/or to delay the payment of any monies and/or provision of any benefits in such manner as may be determined by the Company, in its discretion, to be necessary or appropriate to comply with Section 409A of the Code without prior notice to or consent of the Grantee.  The Grantee hereby releases and holds harmless the Company, its directors, officers and stockholders from any and all claims that may arise from or relate to any tax liability, penalties, interest, costs, fees or other liability incurred by the Grantee in connection with this Agreement, including as a result of the application of Section 409A of the Code.
		

		
			 
		

		
			10.4Advice of Independent Tax Advisor. The Company has not obtained a tax ruling or other confirmation from the Internal Revenue Service with regard to the application of Section 409A to this Agreement, and the Company does not represent or warrant that this Agreement will avoid adverse tax consequences to the Grantee, including as a result of the application of Section 409A of the Code. The Grantee hereby acknowledges that he or she has been advised to seek the advice of his or her own independent tax advisor prior to entering into this Agreement and is not relying upon any representations of the Company or any of its agents as to the effect of or the advisability of entering into this Agreement.
		

		
			 
		

		
			11.ADMINISTRATION.
		

		
			 
		

		
			All questions of interpretation concerning this Agreement or any other form of agreement or other document employed by the Company in the administration of this Agreement shall be determined by the Board. All such determinations by the Board shall be final, binding and conclusive upon all persons having an interest in this Agreement, unless fraudulent or made in bad faith. Any and all actions, decisions and determinations taken or made by the Board in the exercise of its discretion pursuant to this Agreement or other agreement thereunder (other than determining questions of interpretation pursuant to the preceding sentence) shall be final, binding and conclusive upon all persons having an interest in this Agreement.  Any officer of the Company shall have the authority to act on behalf of the Company with respect to any matter, right, obligation, or election which is the responsibility of or which is allocated to the Company herein, provided the officer has apparent authority with respect to such matter, right, obligation, or election.
		

		
			
		

		 

		

			 

		

 

		
			12.REPRESENTATIONS AND WARRANTIES OF GRANTEE.
		

		
			 
		

		
			In connection with the acquisition of securities pursuant to this Agreement, the Grantee hereby agrees, represents and warrants as follows:
		

		
			 
		

		
			12.1Investment Intent.  The Grantee is acquiring shares of Stock pursuant to this Agreement solely for the Grantee’s own account for investment and not with a view to or for sale in connection with any distribution of the shares or any portion thereof and not with any present intention of selling, offering to sell or otherwise disposing of or distributing the shares or any portion thereof in any transaction other than a transaction exempt from registration under the Securities Act.  The Grantee further represents that the entire legal and beneficial interest of the shares is being acquired, and will be held, for the account of the Grantee only and neither in whole nor in part for any other person.
		

		
			 
		

		
			12.2Absence of Solicitation.  The Grantee was not presented with or solicited by any form of general solicitation or general advertising, including, but not limited to, any advertisement, article, notice, or other communication published in any newspaper, magazine, or similar media, or broadcast over television, radio or similar communications media, or presented at any seminar or meeting whose attendees have been invited by any general solicitation or general advertising.
		

		
			 
		

		
			12.3Capacity to Protect Interests.  The Grantee has either (a) a preexisting personal or business relationship with the Company or any of its officers, directors, or controlling persons, consisting of personal or business contacts of a nature and duration to enable the Grantee to be aware of the character, business acumen and general business and financial circumstances of the person with whom such relationship exists, or (b) such knowledge and experience in financial and business matters (or has relied on the financial and business knowledge and experience of the Grantee’s professional advisor who is unaffiliated with and who is not, directly or indirectly, compensated by the Company or any affiliate or selling agent of the Company) as to make the Grantee capable of evaluating the merits and risks of the investment in shares acquired pursuant to this Agreement and to protect the Grantee’s own interests in the transaction, or (c) both such relationship and such knowledge and experience.
		

		
			 
		

		
			12.4Registered Securities.    The issuance to Grantee of shares pursuant to this Agreement has been registered under the Securities Act under the Form S-8 November 18, 2013.
		

		
			 
		

		
			 
		

		
			13.MISCELLANEOUS PROVISIONS.
		

		
			 
		

		
			13.1Termination or Amendment.  The Board may terminate or amend this Agreement at any time; provided, however, no such termination or amendment may adversely affect the Grantee’s rights under this Agreement without the consent of the Grantee unless such termination or amendment is necessary to comply with applicable law or government regulation, including, but not limited to, Section 409A of the Code.  No amendment or addition to this Agreement shall be effective unless in writing.
		

		
			 
		

		
			13.2Non-transferability of Units.  Prior to the issuance of shares of Stock on the applicable Settlement Date, neither this Agreement nor any Units subject to this Agreement shall be subject in any manner to anticipation, alienation, sale, exchange, transfer, assignment, pledge, encumbrance, or garnishment by creditors of the Grantee or the Grantee’s beneficiary, except transfer by will or by the laws of descent and distribution.  All rights with respect to this Agreement shall be exercisable during the Grantee’s lifetime only by the Grantee or the Grantee’s guardian or legal representative.
		

		
			 
		

		
			13.3Further Instruments.  The parties hereto agree to execute such further instruments and to take such further action as may reasonably be necessary to carry out the intent of this Agreement.
		

		
			 
		

		
			13.4Binding Effect.  This Agreement shall inure to the benefit of the successors and assigns of the Company and, subject to the restrictions on transfer set forth herein, be binding upon the Grantee and the Grantee’s heirs, executors, administrators, successors and assigns.
		

		
			
		

		 

		

			 

		

 

		
			13.5Delivery of Documents and Notices.  Any document relating to this Agreement or any notice required or permitted hereunder shall be given in writing and shall be deemed effectively given (except to the extent that this Agreement provides for effectiveness only upon actual receipt of such notice) upon personal delivery, electronic delivery at the e-mail address, if any, provided for the Grantee by a Participating Company, or upon deposit in the U.S. Post Office or foreign postal service, by registered or certified mail, or with a nationally recognized overnight courier service, with postage and fees prepaid, addressed to the other party at the address of such party set forth below or at such other address as such party may designate in writing from time to time to the other party.
		

		
			 
		

		
			(a)Description of Electronic Delivery.  This Agreement and any reports of the Company provided generally to the Company’s stockholders may be delivered to the Grantee electronically.  Such means of electronic delivery may include but do not necessarily include the delivery of a link to a Company intranet or the Internet site of a third party involved in administering this Agreement, the delivery of the document via e-mail or such other means of electronic delivery specified by the Company.
		

		
			 
		

		
			(b)Consent to Electronic Delivery.  The Grantee acknowledges that the Grantee has read Section 13.5(a) of this Agreement and consents to the electronic delivery of the documents described in such Section.  The Grantee acknowledges that he or she may receive from the Company a paper copy of any documents delivered electronically at no cost to the Grantee by contacting the Company by telephone or in writing.  The Grantee further acknowledges that the Grantee will be provided with a paper copy of any documents if the attempted electronic delivery of such documents fails.  The Grantee may revoke his or her consent to the electronic delivery of documents described in Section 13.5(a) or may change the electronic mail address to which such documents are to be delivered (if Grantee has provided an electronic mail address) at any time by notifying the Company of such revoked consent or revised e-mail address by telephone, postal service or electronic mail.  Finally, the Grantee understands that he or she is not required to consent to electronic delivery of documents described in Section 13.5(a).
		

		
			 
		

		
			13.6Integrated Agreement. This Agreement, together with the Employment Agreement, shall constitute the entire understanding and agreement of the Grantee and the Company with respect to the subject matter contained herein and shall supersede any prior agreements, understandings, restrictions, representations, or warranties between the Grantee and the Company with respect to such subject matter.  To the extent contemplated herein, the provisions of this Agreement shall survive any settlement of the Units and shall remain in full force and effect.
		

		
			 
		

		
			13.7Applicable Law. This Agreement will be governed by the laws of the State of California, without giving effect to the conflict of law principles thereof. For purposes of litigating any dispute that arises under this Agreement, the parties hereby submit to and consent to the jurisdiction of the State of California, and agree that such litigation will be conducted in the courts of San Diego County, California, or the federal courts for the United States for the Southern District of California, and no other courts, where this Agreement is made and/or to be performed.
		

		
			 
		

		
			13.8Counterparts.  This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.
		

		
			 
		

		
			[Remainder of Page Left Intentionally Blank]
		

		
			 
		

		
			 
		

		
			 
		

		
			
		

		
			

		 

		

			 

		

 

 
		

			
					
						 

					
					
						 

					
					
						 

					
					
						PURE BIOSCIENCE, INC.

				
	
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						 

				
	
					
						Date:

					
					
						 

					
					
						 

					
					
						By:

					
					
						 

				
	
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						Dave Pfanzelter, Chairman

				

		
			 
		

		
			ACCEPTANCE
		

		
			 
		

		
			The Grantee represents that the Grantee has read and is familiar with the terms and provisions of this Agreement and hereby accepts the Award subject to all of the terms and provisions hereof.  The Grantee hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Board of Directors of the Company upon any questions arising under this Agreement.
		

		
			 
		

			
					
						 

					
					
						 

					
					
						 

					
					
						GRANTEE

				
	
					
						 

					
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						 

					
					
						 

					
					
						 

				
	
					
						Date:

					
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						 

					
					
						 

					
					
						 

				

		
			 
		

		
			
		

		
			

		 

		

			 

		

 

Exhibit A
		

		
			 
		

		
			Employment Agreement

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00250-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00250-of-00352.parquet"}]]